| Literature DB >> 34422376 |
Berdel Akmaz1,2, Sander M J van Kuijk3, Peyman Sardari Nia2.
Abstract
BACKGROUND: Surgeon volume has been identified as a possible factor that influences outcomes in mitral valve (MV) surgery. The aim of this study was to systematically review all published studies on the association between individual surgeon volume and outcome in MV surgery.Entities:
Keywords: Mitral valve surgery (MV surgery); mortality; reoperation; repair rate; surgeon volume
Year: 2021 PMID: 34422376 PMCID: PMC8339780 DOI: 10.21037/jtd-21-578
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1PRISMA flow diagram of the study selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis.
Characteristics of included studies
| Authors | Study period | Setting (database) | Study design | MV repair or replacement | Procedures in total (% male/female) | Age (years) | Outcome measure | Conclusion |
|---|---|---|---|---|---|---|---|---|
| Badhwar | 2011–2016 | United States (Society of Thoracic Surgeons Adult Cardiac Surgery Database) | Retrospective cohort study | MV repair and replacement | 55,311 (57%/43%) | 64 [56–73] | Operative mortality, 30-day mortality, 30-day weighted composite of mortality/morbidity, successful repair rate, 1-year mortality, reoperation, heart failure re-hospitalization | Surgeon volume was associated with repair rates, 30-day operative mortality, 1-year mortality |
| Bolling | 2005–2007 | North America (Society of Thoracic Surgeons Adult Cardiac Surgery Database) | Retrospective cohort study | MV repair and replacement | 28,507 (48.7%/51.3%) | 62 [52–72] | Repair rate | Likelihood of repair is heavily influenced by surgeon volume |
| Chikwe | 2002–2013 | New York State (Statewide Planning and Research Cooperative System) | Retrospective cohort study | MV repair (n=3,660) and replacement (n=1,815) | 5,475 (49%/51%) | 59.3 | All-cause mortality, repair rates, survival, post-repair reoperations | Total annual surgeon volume of <25 operations was associated with lower repair rates, increased 1-year mortality and less freedom from reoperation |
| Ch’ng | 2001–2010 | Australia and New Zealand (Australian and New Zealand Society of Cardiac and Thoracic Surgeons) | Retrospective cohort study | All valve surgery | 11,536 (62.7%/37.3%) | 67.5 | 30-day perioperative mortality, perioperative complications | Procedure-specific volume and mortality are significantly associated |
| Hannan | 2008–2014 | New York State (New York’s Cardiac Surgery Reporting System) | Retrospective cohort study | MV repair and replacement | 2,259 (53.4%/46.6%) | 60.9 | Mortality, postoperative stroke, congestive heart failure, reoperation, repair rate | No significant difference in mortality among the surgeon volume quartiles |
| Kilic | 2003–2008 | 44 states in the US (NIS database) | Retrospective cohort study | MV repair and replacement | 50,152 (52.7%/47.3%) | 61.9 | Operative mortality, | Irrespectively of hospital volume, low surgeon volume significantly increased operative mortality. MV repair rates differ significantly across surgeon volume strata |
| LaPar | 2001–2011 | Virginia (Virginia Cardiac Surgery Quality Initiative Data Registry) | Retrospective cohort study | MV repair (n=2,516) and MV replacement (n=1,662) | 4,194 (54.1%/45.9%) | 62.96 | Repair rate | Surgeon volume was more significantly associated than hospital volume with an increased likelihood for repair |
MV, mitral valve.
Study quality assessment according to the NOS
| Authors | NOS | ||||
|---|---|---|---|---|---|
| Selection | Comparability | Outcome | Total (maximum 8) | Quality judgementa | |
| Badhwar | 4 | 1 | 2 | 7 | High |
| Bolling | 4 | 1 | 1 | 6 | Fair |
| Chikwe | 4 | 1 | 3 | 8 | High |
| Ch’ng | 4 | – | 2 | 6 | Fair |
| Hannan | 4 | 1 | 2 | 7 | High |
| Kilic | 4 | 1 | 1 | 6 | Fair |
| LaPar | 4 | 1 | 2 | 7 | High |
a, ≤5: low methodological quality, 6: fair methodological quality, ≥7: high methodological quality. NOS, Newcastle-Ottawa Scale.
Results of included studies regarding repair rate
| Authors | Surgeon volumes | Repair rate (%) per surgeon volume | AOR/OR (95% CI) | P value |
|---|---|---|---|---|
| Badhwar | Attempted repair rate: | Attempted repair rate: | Attempted repair high | |
| <5.3 MVO | 77.7% | AOR: 0.34 (0.29–0.41) | <0.001 | |
| >20.9 MVO | 87.2% | |||
| Successful repair rate: | Successful repair rate: | Successful repair high | ||
| <5.3 MVO | 96.7% | AOR: 0.62 (0.45–0.85) | 0.003 | |
| >20.9 MVO | 97.3% | |||
| Bolling | Subgroup analysis: | Subgroup analysis: | AOR: | |
| 5 MVO | 54.6% | 5 MVO: reference | ||
| 10 MVO | 60.4% | 10 MVO: 1.5 (1.4–1.6) | Unknown | |
| 20 MVO | 69.6% | 20 MVO: 2.5 (2.0–3.0) | ||
| 50 MVO | 80.8% | 50 MVO: 5.0 (4.0–6.0) | ||
| 100 MVO | 82.6% | 100 MVO: 5.5 (3.5–7.0) | ||
| Chikwe | AOR: | |||
| <10 MVO | 48.4% | <10 MVO: reference | ||
| 11–24 MVO | 55.8% | 11–24 MVO: 1.22 (0.89-1.70)a | Unknown | |
| 25–50 MVO | 64.6% | 25–50 MVO: 1.77 (1.26–2.49) | ||
| >51 MVO | 77.2% | >51 MVO: 3.18 (2.02–5.00) | ||
| Kilic | OR: | |||
| 10 MVO | 49% | 10 MVO: reference | ||
| 25 MVO | 53% | 25 MVO: 1.17 (0.67–2.04)a,b | 0.572c | |
| 100 MVO | 67% | 100 MVO: 2.11 (1.19–3.75)b | 0.01c | |
| LaPar | AOR: | |||
| <20 MVO | 39% | 1.25 (1.04–1.72) | <0.0001 | |
| >20 MVO | 67% | |||
| Hannan | AOR: | |||
| <17 MVO | 69% | <17 MVO: reference | ||
| 18–30 MVO | 74% | 18–30 MVO: 1.27 (0.69–2.37)a,b | 0.434c | |
| 31–46 MVO | 84% | 31–46 MVO: 2.36 (1.19–4.67)b | 0.014c | |
| >47 MVO | 92% | >47 MVO: 5.17 (2.24–11.94)b | 0.0001c |
a, not significant; b, OR was not given in the article and was calculated by the authors; c, P value was not given in the article and was calculated by the authors. AOR, adjusted odds ratio; CI, confidence interval; MVO, mitral valve operations; OR, odds ratio.
Results of included studies regarding mortality
| Authors | Surgeon volumes | Mortality (%) per surgeon volume | AOR/HR (95% CI) | P value |
|---|---|---|---|---|
| Badhwar | Operative mortality: | Operative mortality: | High volume as reference: | |
| <5.3 MVO | 1.42% | AOR: 2.27 (1.69–3.04) | <0.0001 | |
| >20.9 MVO | 0.70% | |||
| 30-day mortality: | 30-day mortality: | High volume as reference: | ||
| <5.3 MVO | 1.53% | AOR: 2.25 (1.68–3.01) | <0.001 | |
| >20.9 MVO | 0.99% | |||
| 1-year mortality: | 1-year mortality: | High volume as reference: | ||
| <5.3 MVO | 9.37% | AHR: 1.60 (1.32–1.93) | Unknown | |
| >20.9 MVO | 6.11% | |||
| Chikwe | 1-year mortality: | 1-year mortality: | AHR: | |
| <10 MVO | 5.9% | <10: reference | ||
| 11–24 MVO | 4.2% | 11–24 MVO: 0.72 (0.42–1.22)a | ||
| 25–50 MVO | 3% | 25–50 MVO: 0.52 (0.31–0.85) | Unknown | |
| >51 MVO | 2.2% | >51 MVO: 0.46 (0.28–0.76) | ||
| Ch’ng | 30-day mortality: | 30-day mortality: | OR per 20 extra operations: | |
| 3 MVO | 0% | 0.84 (0.74–0.95) | 0.003 | |
| 10 MVO | 12% | OR per volume group: | ||
| 20 MVO | 7% | 10 MVO: reference | ||
| 50 MVO | 4% | 20 MVO: 0.55 (0.50–0.60)b | <0.0001c | |
| 110 MVO | 2% | 50 MVO: 0.31 (0.27–0.34)b | <0.0001c | |
| 110 MVO: 0.15 (0.13–0.17)b | <0.0001c | |||
| Hannan | 4-year mortality: | 4-year mortality: | >47 MVO | |
| <17 MVO | 5.5% | AHR: 0.63 (0.36–1.09)a | 0.15 | |
| 18–30 MVO | 5.1% | AOR: >47 MVO | ||
| 31–46 MVO | 5.9% | 0.65 (0.18–2.39)a,b | 0.519c | |
| >47 MVO | 4.1% | |||
| Kilic | Operative mortality: | Operative mortality: | OR (multivariate analysis): | |
| 1–6.5 MVO | 10.1% | 1–6.5 MVO: 2.22 (1.53–3.23) | <0.001 | |
| 6.6–20.5 MVO | 6.1% | 6.6–20.5 MVO: 1.50 (1.07–2.11) | 0.02 | |
| >20.5 MVO | 4.6% | >20.5 MVO: reference |
a, not significant; b, OR was not given in the article and was calculated by the authors; c, P value was not given in the article and was calculated by the authors. AOR, adjusted odds ratio; HR, hazard ratio; CI, confidence interval; MVO, mitral valve operations; OR, odds ratio.
Results of included studies regarding reoperations
| Authors | Surgeon volumes | Freedom from reoperation (%) at 1 year | AHR/HR (95% CI) | P value |
|---|---|---|---|---|
| Badhwar | <5.3 MVO | 1.07 | HR: 1.14 (0.60–2.18)a | Unknown |
| >20.9 MVO | 0.95 | |||
| Chikwe | <25 MVO | 3.6 | AHR: 0.45 (0.26–0.76) | 0.003 |
| >25 MVO | 1.3 |
a, not significant. AHR, adjusted hazard ratio; HR, hazard ratio; CI, confidence interval; MVO, mitral valve operations.
Proposed threshold values that led to better outcomes
| Study | Outcome measures | Threshold value |
|---|---|---|
| Bolling | Repair rate | 40 |
| LaPar | Repair rate | 20 |
| Chikwe | Repair rate, mortality, reoperation | 25 |
| Badhwar | Repair rate, mortality | 35 |